VRDN-001 demonstrated positive preliminary results in the treatment of chronic thyroid eye disease in an ongoing phase 1/2 clinical trial, according to a press release from Viridian Therapeutics.
The trial is investigating two infusions of the full antagonist antibody administered intravenously at doses of 10 mg/kg and 3 mg/kg, with clinical activity endpoints measured at 6 weeks after the first infusion. Each cohort included six patients randomly assigned to receive VRDN-001 and two patients randomly assigned to receive placebo. Changes in proptosis, clinical activity score (CAS) and diplopia